FAQ: Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) 2024 Financial Turnaround and Business Overview
Summary
Scinai Immunotherapeutics Ltd. reported a significant financial turnaround in 2024, with a $4.8 million net gain driven by a loan-to-equity conversion, marking a stark contrast to its $6.5 million loss in 2023 and achieving its first revenue from CDMO services.
What contributed to Scinai Immunotherapeutics Ltd.’s net gain in 2024?
The $4.8 million net gain was largely due to $14.8 million in financial income from a loan-to-equity conversion, alongside the company’s first revenue of $658,000 from its CDMO unit.
How does Scinai Immunotherapeutics Ltd.’s 2024 performance compare to 2023?
In 2024, the company reversed a $6.5 million loss from 2023 to a $4.8 million net gain, thanks to financial income from a loan-to-equity conversion and its first revenue from CDMO services.
What are the two main business units of Scinai Immunotherapeutics Ltd.?
Scinai operates two business units: one focused on developing inflammation and immunology biological therapeutic products, and a boutique CDMO providing drug development and manufacturing services to early stage biotech companies.
Where can I find more information about Scinai Immunotherapeutics Ltd.?
For more information, visit the company’s website at www.Scinai.com or the latest news and updates at https://ibn.fm/SCNI.
What was Scinai Immunotherapeutics Ltd.’s revenue in 2024 and from what source?
The company posted $658,000 in revenue in 2024, its first ever, from its CDMO unit.
How did Scinai Immunotherapeutics Ltd.’s R&D and G&A expenses change in 2024?
R&D expenses remained steady at $5.6 million, while G&A costs dropped to $2.6 million in 2024.
What was the cash and equivalents total for Scinai Immunotherapeutics Ltd. at the end of 2024?
Cash and equivalents totaled $1.9 million at year-end 2024.
What is BioMedWire and how does it relate to Scinai Immunotherapeutics Ltd.?
BioMedWire is a specialized communications platform focusing on biotechnology and life sciences sectors, which published the press release about Scinai Immunotherapeutics Ltd.’s 2024 financial results. More about BioMedWire can be found at https://www.biomedwire.com/.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 114674